ArticleUrology2018
National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms.
Article in Urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Racial Differences in Care Quality Among Men With Newly Diagnosed Prostate Cancer.JAMA network open · 2025Article
- Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer.Cancer medicine · 2025Article
- Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.Cancer · 2025Article
- Association Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care.Urology practice · 2024Article
- Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.Cancer medicine · 2024Article
- Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.JCO clinical cancer informatics · 2023Article
- Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?Urologic oncology · 2023Article
- Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol.European urology open science · 2023Article
- Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.The Journal of urology · 2021Article
- Understanding Active Surveillance for Prostate Cancer.JCO oncology practice · 2021Article
- Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.Urology · 2021Article
- Primary Care Physician Perspectives on Low Risk Prostate Cancer Management: Results of a National Survey.Urology practice · 2021Article
- Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.Urologic oncology · 2021Article
- Article
- Trends in treatments for prostate cancer in the United States, 2010-2015.American journal of cancer research · 2021Article
- Associations of multimorbidity and patient-reported experiences of care with conservative management among elderly patients with localized prostate cancer.Cancer medicine · 2020Article
- Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS).Journal of the National Cancer Institute. Monographs · 2020Article
- Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.European urology · 2020Article
- Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.European urology focus · 2020Article
- Practice-Level Adoption of Conservative Management for Prostate Cancer.Journal of oncology practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo better describe the real-world use of active surveillance. Active surveillance is a preferred management option for low-risk prostate cancer, yet its use outside of high-volume institutions is poorly understood. We created multiple claims-based algorithms, validated them using a robust clinical registry, and applied them to Medicare claims to describe national utilization. MATERIALS AND
methodsWe identified men with prostate cancer from 2012-2014 in a 100% sample of Michigan Medicare data and linked them with the Michigan Urologic Surgery Improvement Collaborative (MUSIC) registry. Using MUSIC treatment assignment as the standard, we determined the performance of 8 claims-based algorithms to identify men on active surveillance. We selected 3 algorithms (the most sensitive, the most specific, and a balanced algorithm incorporating age and comorbidity) and applied them to a 20% national Medicare sample to describe national trends.
resultsWe identified 1186 men with incident prostate cancer and completely linked data. Eight algorithms were tested with sensitivity ranging from 23.5% to 88.2% and specificity ranging from 93.5% to 99.1%. We found that the use of surveillance for men with incident prostate cancer increased from 2007 to 2014, nationally. However, among all men in the population, there was a large decrease in the rate of prostate cancer diagnosis and an increased or stable rate in the use of active surveillance, depending on the algorithm used. Less than 25% of men on active surveillance underwent a confirmatory prostate biopsy.
conclusionWe describe the performance of claims-based algorithms to identify active surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.